Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
54.38
+0.56 (1.04%)
At close: Jun 6, 2025, 4:00 PM
54.00
-0.38 (-0.70%)
After-hours: Jun 6, 2025, 7:38 PM EDT
Protagonist Therapeutics Employees
Protagonist Therapeutics had 126 employees as of December 31, 2024. The number of employees increased by 14 or 12.50% compared to the previous year.
Employees
126
Change (1Y)
14
Growth (1Y)
12.50%
Revenue / Employee
$1,649,214
Profits / Employee
$445,976
Market Cap
3.37B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
PTGX News
- 5 days ago - Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Business Wire
- 16 days ago - Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - Accesswire
- 4 weeks ago - Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 6 weeks ago - Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - Accesswire
- 7 weeks ago - Protagonist Therapeutics Reports Granting of Inducement Award - Accesswire
- 2 months ago - Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Accesswire
- 3 months ago - Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It - Seeking Alpha
- 3 months ago - Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Benzinga